/ JAMA Network Open
Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
Herbrand AK, Schmitt AM, Briel M, Ewald H, Goldkuhle M, Diem S, Hoogkamer A, Joerger M, Moffa G, Novak U, Hemkens LG, Kasenda B.
JAMA Network Open
2021 Mar 1;4(3):e210380. doi: 10.1001/jamanetworkopen.2021.0380. PMID: 33651108; PMCID: PMC7926292.
This joint project of Clinical Epidemiology and Oncology at the University Hospital Basel (USB) investigates the evidence of off-label use in oncology and the associated cost reimbursement by Swiss health insurers based on routine data of more than 5800 patients. The study indicates that a survival benefit from off-label therapy demonstrated in randomized trials has no clear influence on whether or not patients receive cost reimbursement and thus access to the therapy.